Patents by Inventor Binxi GE

Binxi GE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lipid compound as well as lipid carrier, nucleic acid lipid nanoparticle composition and pharmaceutical preparation containing same
    Patent number: 11690922
    Abstract: The present invention belongs to the technical field of gene therapy, and particularly relates to a series of lipid compounds as well as a lipid carrier, nucleic acid lipid nanoparticle composition and pharmaceutical preparation containing the same. A compound having a structure of a formula (I) provided by the present invention can be used for preparing a lipid carrier together with other lipid compounds, and exhibits pH response, and the entrapment efficiency to a nucleic acid drug is high, which greatly improves in-vivo delivery efficiency of the nucleic acid drug; and furthermore, a lipid compound with a specific structure can be chosen as a lipid carrier based on an organ in which the nucleic acid drug needs to be enriched, having a good market application prospect.
    Type: Grant
    Filed: July 21, 2022
    Date of Patent: July 4, 2023
    Assignee: Purecodon (Hong Kong) Biopharma Ltd.
    Inventors: Ke Huang, Binxi Ge, Yingwen Li, Yuping Liu, Yinjia Gao, Zhenhua Sun
  • LIPID COMPOUND AS WELL AS LIPID CARRIER, NUCLEIC ACID LIPID NANOPARTICLE COMPOSITION AND PHARMACEUTICAL PREPARATION CONTAINING SAME
    Publication number: 20230093138
    Abstract: The present invention belongs to the technical field of gene therapy, and particularly relates to a series of lipid compounds as well as a lipid carrier, nucleic acid lipid nanoparticle composition and pharmaceutical preparation containing the same. A compound having a structure of a formula (I) provided by the present invention can be used for preparing a lipid carrier together with other lipid compounds, and exhibits pH response, and the entrapment efficiency to a nucleic acid drug is high, which greatly improves in-vivo delivery efficiency of the nucleic acid drug; and furthermore, a lipid compound with a specific structure can be chosen as a lipid carrier based on an organ in which the nucleic acid drug needs to be enriched, having a good market application prospect.
    Type: Application
    Filed: July 21, 2022
    Publication date: March 23, 2023
    Inventors: Ke HUANG, Binxi GE, Yingwen LI, Yuping LIU, Yinjia GAO, Zhenhua SUN